Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ROCK2 | O75116 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 4/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.40 |
| ▸ | ELANE | P08246 | 1/20 | 0.39 |
| ▸ | PRKCA | P17252 | 1/20 | 0.38 |
| ▸ | PRKCD | Q05655 | 1/20 | 0.38 |
| ▸ | NPR3 | P17342 | 1/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.36 |
| ▸ | LMNA | P02545 | 3/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | THRB | P10828 | 1/20 | 0.36 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19901428 | 0.92 | MEN1 (0.54) | ROCK2MEN1KMT2AL3MBTL1SMN1; SMN2 | |
| SCHEMBL1753582 | 0.92 | MEN1 (0.54) | ROCK2MEN1KMT2AL3MBTL1SMN1; SMN2 | |
| SCHEMBL23318499 | 0.88 | ROCK2 (0.42) | ROCK2MEN1KMT2AL3MBTL1SMN1; SMN2 | |
| SCHEMBL19201796 | 0.85 | ROCK2 (0.43) | ROCK2MEN1KMT2AL3MBTL1SMN1; SMN2 | |
| SCHEMBL26549546 | 0.84 | ROCK2 (0.40) | ROCK2MEN1KMT2AL3MBTL1SMN1; SMN2 | |
| SCHEMBL27305897 | 0.83 | ELANE (0.52) | MEN1KMT2AL3MBTL1SMN1; SMN2MAPT | |
| SCHEMBL18792766 | 0.82 | ELANE (0.46) | ROCK2MEN1KMT2AL3MBTL1SMN1; SMN2 | |
| SCHEMBL11946728 | 0.82 | ALDH1A1 (0.55) | MEN1KMT2AL3MBTL1SMN1; SMN2RXFP1 | |
| SCHEMBL9917266 | 0.82 | RXFP1 (0.44) | ROCK2MEN1KMT2AL3MBTL1SMN1; SMN2 | |
| SCHEMBL24541057 | 0.81 | MEN1 (0.43) | ROCK2MEN1KMT2AL3MBTL1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11779649-B2 | Antibodies to PMEL17 and conjugates thereof | NOVARTIS AG (CH) | 2023-10-10 | — | — | US | disclosed |
| US-20230144211-A1 | ANTIFOLATE LINKER-DRUGS AND ANTIBODY-DRUG CONJUGATES | BYONDIS B.V. (NL) | 2023-05-11 | — | — | US | disclosed |
| US-20230027495-A1 | METHODS OF TREATING CANCER WITH A COMBINATION OF AN ANTI-PD-1 ANTIBODY AND AN ANTI-TISSUE FACTOR ANTIBODY-DRUG CONJUGATE | GENMAB A/S (DK) | 2023-01-26 | — | — | US | disclosed |
| US-20220387485-A1 | METHODS OF TREATING CANCER WITH A COMBINATION OF A PLATINUM-BASED AGENT AND AN ANTI-TISSUE FACTOR ANTIBODY-DRUG CONJUGATE | GENMAB A/S (DK) | 2022-12-08 | — | — | US | disclosed |
| US-20220133901-A1 | ROR1 ANTIBODY IMMUNOCONJUGATES | VelosBio Inc. (US) | 2022-05-05 | — | — | US | disclosed |
| US-20220119392-A1 | ANTIFOLATE LINKER-DRUGS AND ANTIBODY-DRUG CONJUGATES | BYONDIS B.V. (NL) | 2022-04-21 | — | — | US | disclosed |
| US-20210228731-A1 | ANTIBODY DRUG CONJUGATES FOR ABLATING HEMATOPOIETIC STEM CELLS | NOVARTIS INSTITUTE FOR FUNCTIONAL GENOMICS, INC. | 2021-07-29 | — | — | US | disclosed |
| US-20210228676-A1 | Combination Therapy With LIV1-ADC and PD-1 Antagonist | MERCK SHARP & DOHME B.V. (NL) | 2021-07-29 | — | — | US | disclosed |
| US-11052155-B2 | Conjugates of CC-1065 analogs and bifunctional linkers | SYNTARGA BV (NL) | 2021-07-06 | — | — | US | disclosed |
| US-20210177987-A1 | ANTI-TISSUE FACTOR ANTIBODY-DRUG CONJUGATES AND THEIR USE IN THE TREATMENT OF CANCER | GENMAB A/S (DK) | 2021-06-17 | — | — | US | disclosed |
| US-20170333567-A1 | Novel Conjugates of CC-1065 Analogs and Bifunctional Linkers | SYNTARGA BV (NL) | 2017-11-23 | — | — | US | disclosed |
| US-9815784-B2 | CC-1065 analogs and their conjugates | SYNTARGA B.V. (NL) | 2017-11-14 | — | — | US | disclosed |
| US-20170274090-A1 | Novel Conjugates of CC-1065 Analogs and Bifunctional Linkers | SYNTARGA BV (NL) | 2017-09-28 | — | — | US | disclosed |
| US-20170252458-A1 | ERIBULIN-BASED ANTIBODY-DRUG CONJUGATES AND METHODS OF USE | MORPHOTEK, INC. | 2017-09-07 | — | — | US | disclosed |
| US-9629924-B2 | Conjugates of CC-1065 analogs and bifunctional linkers | SYNTARGA BV (NL) | 2017-04-25 | — | — | US | disclosed |
| US-9585970-B2 | Site-specific labeling methods and molecules produced thereby | NOVARTIS AG (CH) | 2017-03-07 | — | — | US | disclosed |
| US-8940784-B2 | Water-soluble CC-1065 analogs and their conjugates | SYNTARGA B.V. (NL) | 2015-01-27 | — | — | US | disclosed |
| US-8158590-B2 | Triazole-containing releasable linkers, conjugates thereof, and methods of preparation | SYNTARGA B.V. (NL) | 2012-04-17 | — | — | US | disclosed |
| US-20090318668-A1 | Water-Soluble CC-1065 Analogs and Their Conjugates | Georg-August-Universität Göttingen Stiftung öffentlichen Rechts (ohne Bereich Humanmedizin) (DE) | 2009-12-24 | — | — | US | disclosed |
| US-20080311136-A1 | Triazole-Containing Releasable Linkers, Conjugates Thereof, and Methods of Preparation | BYONDIS B.V. (NL) | 2008-12-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (15 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210228676-A1 | Combination Therapy With LIV1-ADC and PD-1 Antagonist | PDCD1, CD274, PDCD1LG2 | ROCK2 2663/4885MEN1 708/4885KMT2A 978/4885 |
| US-20210177987-A1 | ANTI-TISSUE FACTOR ANTIBODY-DRUG CONJUGATES AND THEIR USE IN THE TREATMENT OF CANCER | F3, F13B, PGF | ROCK2 1097/4885MEN1 1369/4885KMT2A 1914/4885 |
| US-20170274090-A1 | Novel Conjugates of CC-1065 Analogs and Bifunctional Linkers | PCNA, DCLRE1A, CDC5L | ROCK2 4010/4885MEN1 1237/4885KMT2A 1026/4885 |
| US-20090318668-A1 | Water-Soluble CC-1065 Analogs and Their Conjugates | PCNA, DCK, BAD | ROCK2 3469/4885MEN1 2080/4885KMT2A 1501/4885 |
| US-11779649-B2 | Antibodies to PMEL17 and conjugates thereof | GNA15, GNA11, EEA1 | ROCK2 3141/4885MEN1 670/4885KMT2A 864/4885 |
| US-20170333567-A1 | Novel Conjugates of CC-1065 Analogs and Bifunctional Linkers | PCNA, DCLRE1A, CDC5L | ROCK2 4010/4885MEN1 1237/4885KMT2A 1026/4885 |
| US-20210228731-A1 | ANTIBODY DRUG CONJUGATES FOR ABLATING HEMATOPOIETIC STEM CELLS | BCR, ABL1, CD47 | ROCK2 2530/4885MEN1 2274/4885KMT2A 21/4885 |
| US-20230144211-A1 | ANTIFOLATE LINKER-DRUGS AND ANTIBODY-DRUG CONJUGATES | DHFR, FOLR1, MTHFD2 | ROCK2 4155/4885MEN1 1545/4885KMT2A 1224/4885 |
| US-20230027495-A1 | METHODS OF TREATING CANCER WITH A COMBINATION OF AN ANTI-PD-1 ANTIBODY AND AN ANTI-TISSUE FACTOR ANTIBODY-DRUG CONJUGATE | CD274, PDCD1, PDCD1LG2 | ROCK2 1022/4885MEN1 1303/4885KMT2A 1075/4885 |
| US-20080311136-A1 | Triazole-Containing Releasable Linkers, Conjugates Thereof, and Methods of Preparation | PAICS, CD44, TRIM33 | ROCK2 3058/4885MEN1 581/4885KMT2A 2312/4885 |
| US-11052155-B2 | Conjugates of CC-1065 analogs and bifunctional linkers | PCNA, DCLRE1A, CDC5L | ROCK2 3857/4885MEN1 1247/4885KMT2A 1003/4885 |
| US-20170252458-A1 | ERIBULIN-BASED ANTIBODY-DRUG CONJUGATES AND METHODS OF USE | FOLR1, FOLR2, TUBB1 | ROCK2 1748/4885MEN1 3472/4885KMT2A 4423/4885 |
| US-20220133901-A1 | ROR1 ANTIBODY IMMUNOCONJUGATES | RORA, RORB, RORC | ROCK2 1089/4885MEN1 1857/4885KMT2A 1538/4885 |
| US-20220119392-A1 | ANTIFOLATE LINKER-DRUGS AND ANTIBODY-DRUG CONJUGATES | DHFR, FOLR1, MTHFD2 | ROCK2 4155/4885MEN1 1545/4885KMT2A 1224/4885 |
| US-20220387485-A1 | METHODS OF TREATING CANCER WITH A COMBINATION OF A PLATINUM-BASED AGENT AND AN ANTI-TISSUE FACTOR ANTIBODY-DRUG CONJUGATE | F3, TFPI, ADAMTS13 | ROCK2 1875/4885MEN1 1777/4885KMT2A 1811/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.